Symbols

KNSA

Kiniksa·NASDAQ

--(--)

Signals Analysis

Bullish signal 7

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About KNSA

Kiniksa Pharmaceuticals International, Plc

A company that developing drugs for recurrent pericarditis and cardiovascular disease

Industry

Pharmaceutical

Established Date

07/21/2015

Listing Date

05/24/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

315

Fiscal Year Ends

12-31

Website

www.kiniksa.com

Security Type

Common stock

Office address

23 Old Bond Street, Floor 3, London, WIS 4PZ, England, United Kingdom

Business

Introduction

Kiniksa Pharmaceuticals International, plc was established in Bermuda on July 21, 2015. The company changed its registration from Bermuda to the United Kingdom on June 28, 2024. The Company is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic drugs for patients with debilitating diseases with serious unmet medical needs. The company's immunomodulatory combinations ARCALYST, KPL-404 and mavrilimumab target a range of undertreated cardiovascular and autoimmune diseases based on strong biological principles or proven mechanisms, and offer the potential for differentiation.

Earnings Call

Q2/2025

Estimate EPS0.22

Actual EPS0.23

Estimate Revenue145.21M

Actual Revenue156.79M

Kiniksa's Q2 2025: Navigating Contradictions in Sales Strategy, Patient Compliance, and Market Penetration

Jul 29,2025 10:46·
Earnings Decrypt

Company Financials

EPS

KNSA has released its 2025 Q3 earnings. EPS was reported at 0.23, versus the expected 0.37, missing expectations. The chart below visualizes how KNSA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

KNSA has released its 2025 Q3 earnings report, with revenue of 180.85M, reflecting a YoY change of 61.17%, and net profit of 18.43M, showing a YoY change of 245.24%. The Sankey diagram below clearly presents KNSA's revenue sources and cost distribution.